Document is current
Any future updates will be listed below
-
Authors
Ni, Jing
Kabraji, Sheheryar https://orcid.org/0000-0002-5315-7103
Xie, Shaozhen
Wang, Yanzhi
Pan, Peichen
He, Xiaofang
Liu, Zongming
Leone, Jose Palbo
Long, Henry W. https://orcid.org/0000-0001-6849-6629
Brown, Myles A. https://orcid.org/0000-0002-8213-1658
Winer, Eric P.
Dillon, Deborah A. R.
Lin, Nancy U.
Zhao, Jean J. https://orcid.org/0000-0002-4561-5688
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA168504-06A1, R35 CA210057)
U.S. Department of Health & Human Services | National Institutes of Health
Breast Cancer Research Foundation
U.S. Department of Defense (W81XWH-18-1-0491)
- License Information
-
More Information
Article History
Received: 9 November 2020
Accepted: 22 February 2022
First Online: 18 March 2022
Competing interests
: J.N. is a scientific consultant for Geode Therapeutics Inc. J.P.L. has received research funding from Kazia Therapeutics and consults for Minerva Biotechnologies. D.A.R.D. is on the advisory board for Oncology Analytics, Inc and consults for Novartis. N.U.L. has received research funding (to institution) from Genentech, Pfizer, Seattle Genetics, and Merck, and has received honoraria for consulting/advisory board for Daichii Sankyo, Denali Therapeutics, Puma, and the California Institute for Regenerative Medicine. J.J.Z. is a founder and board director of Crimson Biopharm Inc. and Geode Therapeutics Inc. The remaining authors declare no competing interests.
